Payment overview · 2025
General Payments
$66.61
3 reported records · 3 companies
Healthcare provider profile · identity verified
Thomas J. Mccormack, DO
Allopathic & Osteopathic Physicians|Family Medicine · WAREHAM, MA · NPI 1225080005
Verified facts
What the public records show
CMS Open Payments records show Thomas J. Mccormack, DO received $66.61 in general payments during 2025 across 3 reported records.
Stryker Corporation accounted for 35.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Stryker Corporation | Unresolved — no canonical attribution shown | $23.67 | 35.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.00 | 34.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.94 | 29.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $66.61 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MAKO Normalized: mako |
Device | Stryker Corporation | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 536 | 169 |
| Metoprolol Succinate | Metoprolol Succinate | 375 | 112 |
| Lisinopril | Lisinopril | 355 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 333 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 332 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 324 | 106 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 249 | 77 |
| Omeprazole | Omeprazole | 182 | 54 |
| Simvastatin | Simvastatin | 182 | 52 |
| Lorazepam | Lorazepam | 174 | 42 |
| Losartan Potassium | Losartan Potassium | 173 | 46 |
| Gabapentin | Gabapentin | 170 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 155 | 50 |
| Furosemide | Furosemide | 153 | 55 |
| Alprazolam | Alprazolam | 151 | 23 |
| Potassium Chloride | Potassium Chloride | 145 | 34 |
| Eliquis | Apixaban | 144 | 29 |
| Trazodone Hcl | Trazodone Hcl | 143 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 116 | 34 |
| Tramadol Hcl | Tramadol Hcl | 114 | 19 |
| Metformin Hcl | Metformin Hcl | 113 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 36 |
| Celecoxib | Celecoxib | 111 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 19 |
| Metformin Hcl Er | Metformin Hcl | 111 | 37 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 110 | 34 |
| Jardiance | Empagliflozin | 99 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 97 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 30 |
| Alendronate Sodium | Alendronate Sodium | 83 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 83 | 13 |
| Atenolol | Atenolol | 82 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 20 |
| Sertraline Hcl | Sertraline Hcl | 69 | 18 |
| Prednisone | Prednisone | 68 | 38 |
| Irbesartan | Irbesartan | 63 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 63 | 16 |
| Propranolol Hcl | Propranolol Hcl | 63 | 16 |
| Allopurinol | Allopurinol | 61 | 22 |
| Clonazepam | Clonazepam | 58 | suppressed |
| Ozempic | Semaglutide | 57 | suppressed |
| Klor-Con M20 | Potassium Chloride | 56 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 13 |
| Valsartan | Valsartan | 54 | 15 |
| Meloxicam | Meloxicam | 53 | 15 |
| Farxiga | Dapagliflozin Propanediol | 51 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 51 | 15 |
| Xarelto | Rivaroxaban | 51 | 13 |
| Azithromycin | Azithromycin | 50 | 44 |
| Montelukast Sodium | Montelukast Sodium | 49 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 18 |
| Ezetimibe | Ezetimibe | 47 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | suppressed |
| Spironolactone | Spironolactone | 47 | 13 |
| Nystatin | Nystatin | 45 | 18 |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Trulicity | Dulaglutide | 44 | suppressed |
| Glimepiride | Glimepiride | 43 | 11 |
| Benazepril Hcl | Benazepril Hcl | 42 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 38 | suppressed |
| Pregabalin | Pregabalin | 38 | suppressed |
| Finasteride | Finasteride | 37 | 14 |
| Ibuprofen | Ibuprofen | 37 | 13 |
| Donepezil Hcl | Donepezil Hcl | 36 | 12 |
| Fenofibrate | Fenofibrate | 36 | suppressed |
| Lovastatin | Lovastatin | 36 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 36 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 35 | suppressed |
| Carvedilol | Carvedilol | 35 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 14 |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 32 | suppressed |
| Klor-Con M10 | Potassium Chloride | 31 | 12 |
| Bumetanide | Bumetanide | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | 12 |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 29 | suppressed |
| Famotidine | Famotidine | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 19 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Testosterone | Testosterone | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Etodolac | Etodolac | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Folic Acid | Folic Acid | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 12 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Nucynta | Tapentadol Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $66.61 · 3 records | Stryker Corporation | BREZTRI, MAKO, REXULTI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error